The way we handle peptide therapy
On April 23, 2026, the FDA removed twelve clinically meaningful peptides — spanning the tissue-repair and GH-axis categories — from Category 2. The formal review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) on July 23–24 is the next decision point. This page documents how Limitless prescribes, sources, and monitors peptides through that transition window.
Update, November 11, 2026: the July 23–24 meeting took place, and the committee recommended six of the seven peptides it reviewed. HHS has since published an interim enforcement policy covering six peptides; the regulatory timeline below covers both.
Physician-led, fully documented, and never gray market.
Compounded peptides are not the same as approved pharmaceutical drugs. They are prescription therapeutics — prepared by licensed compounding pharmacies, prescribed by a physician for a specific patient, and monitored on a defined schedule. At Limitless, that is the only way a peptide ever reaches a patient.
We do not stock, sell, resell, or refer patients to retail or online peptide vendors. Every peptide a Limitless patient receives originates from a state-licensed 503A or FDA-registered 503B pharmacy under a valid prescription written by Dr. Joshua Hare, DO.
How we operate inside the compliant lane.
1. Licensed Sourcing
Every peptide originates from a 503A pharmacy with a current state board license, valid PIC (pharmacist-in-charge), and clean inspection record — or from an FDA-registered 503B outsourcing facility for higher-volume preparations. We maintain primary and secondary supplier relationships to prevent inventory gaps.
2. Valid Prescription
A peptide is prescribed only after a clinical evaluation, lab review, and identification of an indication consistent with current evidence. Each prescription is patient-specific. Standing orders, "office stock" peptides, and direct-to-consumer sales are not part of the Limitless model.
3. Informed Consent
Before initiating therapy, each patient signs a written informed consent acknowledging that compounded peptides are not FDA-approved drugs, that supporting evidence varies by molecule, that on- and off-target effects are possible, and that monitoring is required. Consent forms are stored in the patient portal and refreshed annually.
4. Defined Monitoring
Each protocol carries a written monitoring plan: baseline labs, follow-up labs at defined intervals, symptom check-ins, and stop criteria. NAD+ patients have hepatic and energy-marker review. Tesamorelin patients have IGF-1, glucose, and DEXA review. GH-secretagogue patients have IGF-1 and HbA1c review. Tissue-repair peptide patients receive structured progress checks.
Why our peptide menu is deliberately shorter than some.
You will see peptides advertised by name on other clinics' menus that you will not find on ours. That is a choice, not an oversight. The clearest example in 2026 is certain GH-axis agents: we removed them from our standing protocols once the regulatory picture was settled. They are not lawfully compoundable for human use under current FDA status, and they are not on the July 23–24 PCAC docket — meaning even a favorable outcome there would not change their status without separate, multi-year rulemaking. So we do not prescribe them, and we do not advertise them.
We apply the same discipline to a libido peptide — kept off default protocols and used only when a specific patient indication justifies it, and only where lawful. The principle is simple: we don't put anything on the menu we can't legally compound and clinically stand behind. A shorter list is the signature of a clinic reading the regulations, not a limitation of one.
If you are comparing regenerative medicine clinics, it is a fair and useful question to ask any of them: "Is everything you offer currently legal to compound — and how do you know?" The answer tells you how a clinic will handle the rest of your care.
What changed on April 23 — and what the July 23–24 PCAC review still decides.
Update, October 8, 2026: the July 23–24 meeting has taken place, and the committee recommended six of the seven peptides it reviewed. The recommendation is advisory; our post-vote analysis covers what it changes and what it does not yet change.
Update, November 5, 2026: on October 30, HHS published an interim enforcement policy covering six peptides: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. DSIP, the seventh peptide FDA's advisory committee reviewed, is not covered. HHS says it does not intend to take enforcement action against compounding that meets the policy's conditions until a final rule addresses each peptide. The policy is not binding, the Federal Register notice calls it a draft and sets a two-week comment period, and none of the six has been added to the 503A bulks list. The rest of this section is kept as it was published in May.
For the past several years, the FDA had placed a number of clinically meaningful peptides on Category 2 — a status that meaningfully restricted compounding access. Following the February 2026 HHS announcement, twelve peptides were removed from Category 2 effective April 23, 2026.
It is important to be precise about what that change does and does not do. Removal from Category 2 cleared one regulatory barrier. It did not, by itself, place these peptides on the 503A bulk drug substances list — the list that authoritatively governs what 503A pharmacies may compound from bulks. That decision rests with the PCAC's formal review on July 23–24, 2026, and the FDA's subsequent determination. In the meantime, licensed 503A and 503B pharmacies are operating in a transition status: most are filling patient-specific prescriptions written by physicians for indicated uses, while exercising heightened documentation and patient-counseling standards in anticipation of the July decision.
This is the regulatory posture Limitless has chosen to operate inside. We do not assume the July decision is a foregone conclusion. We document accordingly.
Reclassification does not make these peptides FDA-approved drugs. They remain prescription therapeutics with a still-evolving evidence base. They should be used with the same physician oversight and documentation that any specialty therapeutic warrants — and that is the standard we hold ourselves to, regardless of how the July decision lands.
What every Limitless peptide patient can expect.
- A documented clinical reason for every peptide on your protocol.
- A pharmacy of origin you can verify, with a copy of the prescription on file in your portal.
- An informed-consent document you sign once per year.
- A written monitoring plan with baseline and follow-up labs, plus symptom check-ins.
- A direct line to the medical team if a question or side effect comes up.
- A clear stop point — protocols are not indefinite by default.
Ready to begin the right way?
A 30-minute consultation, a full lab panel, and a physician-built protocol — sourced, prescribed, and monitored to a documented standard.
Request a consultation